Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications.
J Mol Cell Cardiol
; 164: 69-82, 2022 03.
Article
in English
| MEDLINE | ID: covidwho-1531870
ABSTRACT
The global propagation of SARS-CoV-2 leads to an unprecedented public health emergency. Despite that the lungs are the primary organ targeted by COVID-19, systemic endothelial inflammation and dysfunction is observed particularly in patients with severe COVID-19, manifested by elevated endothelial injury markers, endotheliitis, and coagulopathy. Here, we review the clinical characteristics of COVID-19 associated endothelial dysfunction; and the likely pathological mechanisms underlying the disease including direct cell entry or indirect immune overreactions after SARS-CoV-2 infection. In addition, we discuss potential biomarkers that might indicate the disease severity, particularly related to the abnormal development of thrombosis that is a fatal vascular complication of severe COVID-19. Furthermore, we summarize clinical trials targeting the direct and indirect pathological pathways after SARS-CoV-2 infection to prevent or inhibit the virus induced endothelial disorders.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Endothelium, Vascular
/
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Language:
English
Journal:
J Mol Cell Cardiol
Year:
2022
Document Type:
Article
Affiliation country:
J.yjmcc.2021.11.010
Similar
MEDLINE
...
LILACS
LIS